HIHiroshi Ikeda

Hiroshi Ikeda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hiroshi Ikeda has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Toshiaki Hayashi

    Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan

    3 shared publications
  • Yasuhisa Shinomura

    Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan

    3 shared publications
  • Eiichiro Yamamoto

    First Department of Internal Medicine, Sapporo Medical University School of Medicine, S1, W16, Chuo-Ku, Sapporo 060-8543, Japan

    2 shared publications
  • Hideki Asaoku

    Department of Clinical Laboratory, Hiroshima Red Cross and Atomic-bomb Survivors Hospital, 1-9-6 Senda-cho, Naka-ku, Hiroshima 730-8619, Japan

    2 shared publications
  • Hiromu Suzuki

    Division of Molecular Biology, Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo, Japan

    2 shared publications
  • Hiroshi Yasui

    Department of Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan

    2 shared publications

Latest Publications

  • Open Access

    Molecular diagnostics of a single drug-resistant multiple myeloma case using targeted next-generation sequencing

    by Hiroshi Ikeda, Kazuya Ishiguro, Yuka Aoki, Testuyuki Igarashi, Toshiaki Hayashi, Tadao Ishida, Yasushi Sasaki, Takashi Tokino, Yasuhisa Shinomura

    A 69-year-old man was diagnosed with IgG λ-type multiple myeloma (MM), Stage II in October 2010. He was treated with one cycle of high-dose dexamethasone. After three cycles of bortezomib, the patient exhibited slow elevations in the free light-chain levels and developed a significant new increase of serum M protein. Bone marrow cytogenetic analysis revealed a complex karyotype characteristic of malignant plasma cells. To better understand the molecular pathogenesis of this patient, we sequenced for mutations in the entire coding regions of 409 cancer-related genes using a semiconductor-based sequencing platform. Sequencing analysis revealed eight nonsynonymous somatic mutations in addition to several copy number variants, including CCND1 and RB1. These alterations may play roles in the pathobiology of this disease. This targeted next-generation sequencing can allow for the prediction of drug resistance and facilitate improvements in the treatment of MM patients.


  • Open Access

    Correction: Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma

    by Yuka Aoki, Masanori Nojima, Hiromu Suzuki, Hiroshi Yasui, Reo Maruyama, Eiichiro Yamamoto, Masami Ashida, Mitsuhiro Itagaki, Hideki Asaoku, Hiroshi Ikeda, et al.


  • Open Access

    Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma

    by Yuka Aoki, Masanori Nojima, Hiromu Suzuki, Hiroshi Yasui, Reo Maruyama, Eiichiro Yamamoto, Masami Ashida, Mitsuhiro Itagaki, Hideki Asaoku, Hiroshi Ikeda, et al.

    Background: The aim of this study was to clarify the role of global hypomethylation of repetitive elements in determining the genetic and clinical features of multiple myeloma (MM). Methods: We assessed global methylation levels using four repetitive elements (long interspersed nuclear element-1 (LINE-1), Alu Ya5, Alu Yb8, and Satellite-α) in clinical samples comprising 74 MM samples and 11 benign control samples (7 cases of monoclonal gammopathy of undetermined significance (MGUS) and 4 samples of normal plasma cells (NPC)). We also evaluated copy-number alterations using array-based comparative genomic hybridization, and performed methyl-CpG binding domain sequencing (MBD-seq). Results: Global levels of the repetitive-element methylation declined with the degree of malignancy of plasma cells (NPC>MGUS>MM), and there was a significant inverse correlation between the degree of genomic loss and the LINE-1 methylation levels. We identified 80 genomic loci as common breakpoints (CBPs) around commonly lost regions, which were significantly associated with increased LINE-1 densities. MBD-seq analysis revealed that average DNA-methylation levels at the CBP loci and relative methylation levels in regions with higher LINE-1 densities also declined during the development of MM. We confirmed that levels of methylation of the 5' untranslated region of respective LINE-1 loci correlated strongly with global LINE-1 methylation levels. Finally, there was a significant association between LINE-1 hypomethylation and poorer overall survival (hazard ratio 2.8, P = 0.015). Conclusion: Global hypomethylation of LINE-1 is associated with the progression of and poorer prognosis for MM, possibly due to frequent copy-number loss.